Boston University Alzheimer's Disease Center and CTE Center, Boston University School of Medicine, Boston, Massachusetts, USA.
U.S. Department of Veteran Affairs, VA Bedford Healthcare System, Bedford, Massachusetts, USA.
Alzheimers Dement. 2022 Aug;18(8):1523-1536. doi: 10.1002/alz.12508. Epub 2021 Dec 2.
We examined the ability of plasma hyperphosphorylated tau (p-tau) to detect cognitive impairment due to Alzheimer's disease (AD) independently and in combination with plasma total tau (t-tau) and neurofilament light (NfL).
Plasma samples were analyzed using the Simoa platform for 235 participants with normal cognition (NC), 181 with mild cognitive impairment due to AD (MCI), and 153 with AD dementia. Statistical approaches included multinomial regression and Gaussian graphical models (GGMs) to assess a network of plasma biomarkers, neuropsychological tests, and demographic variables.
Plasma p-tau discriminated AD dementia from NC, but not MCI, and correlated with dementia severity and worse neuropsychological test performance. Plasma NfL similarly discriminated diagnostic groups. Unlike plasma NfL or t-tau, p-tau had a direct association with cognitive diagnosis in a bootstrapped GGM.
These results support plasma p-tau for the detection of AD dementia and the use of blood-based biomarkers for optimal disease detection.
我们研究了血浆中过度磷酸化的 tau（p-tau）在独立和联合使用血浆总 tau（t-tau）和神经丝轻链（NfL）的情况下，检测阿尔茨海默病（AD）导致的认知障碍的能力。
使用 Simoa 平台分析了 235 名认知正常（NC）、181 名 AD 轻度认知障碍（MCI）和 153 名 AD 痴呆患者的血浆样本。统计方法包括多项回归和高斯图形模型（GGM），以评估血浆生物标志物、神经心理学测试和人口统计学变量的网络。
血浆 p-tau 可区分 AD 痴呆与 NC，但不能区分 MCI，与痴呆严重程度和神经心理学测试表现较差相关。血浆 NfL 同样可区分诊断组。与血浆 NfL 或 t-tau 不同，p-tau 在经过 bootstrap 的 GGM 中与认知诊断有直接关联。
这些结果支持使用血浆 p-tau 检测 AD 痴呆，并支持使用基于血液的生物标志物进行最佳疾病检测。
